share_log

Merck & Co | 4: Statement of changes in beneficial ownership of securities-10% Owner Merck & Co., Inc.

Merck & Co | 4: Statement of changes in beneficial ownership of securities

默沙東 | 4：持股變動聲明
SEC announcement ·  03/11 15:32
Moomoo AI 已提取核心訊息
Merck & Co., Inc. has engaged in a significant transaction involving the purchase of Harpoon Therapeutics, Inc. (HARP) common stock. On March 11, 2024, Merck & Co. acquired 21,397,205 shares of Harpoon Therapeutics at a price of $23.00 per share. Following this transaction, Merck & Co. holds a total of 1,000 shares in Harpoon Therapeutics. The transaction is currently in progress and reflects a direct ownership type, as indicated in the acquisition log.
Merck & Co., Inc. has engaged in a significant transaction involving the purchase of Harpoon Therapeutics, Inc. (HARP) common stock. On March 11, 2024, Merck & Co. acquired 21,397,205 shares of Harpoon Therapeutics at a price of $23.00 per share. Following this transaction, Merck & Co. holds a total of 1,000 shares in Harpoon Therapeutics. The transaction is currently in progress and reflects a direct ownership type, as indicated in the acquisition log.
默沙東公司參與了一項涉及收購Harpoon Therapeutics, Inc.（HARP）普通股的重大交易。2024 年 3 月 11 日，默沙東公司以每股 23.00 美元的價格收購了 Harpoon Therapeutics 的 21,397,205 股股票。在這筆交易之後，默沙東公司共持有Harpoon Therapeutics的1,000股股份。如收購記錄所示，該交易目前正在進行中，屬於直接所有權類型。
默沙東公司參與了一項涉及收購Harpoon Therapeutics, Inc.（HARP）普通股的重大交易。2024 年 3 月 11 日，默沙東公司以每股 23.00 美元的價格收購了 Harpoon Therapeutics 的 21,397,205 股股票。在這筆交易之後，默沙東公司共持有Harpoon Therapeutics的1,000股股份。如收購記錄所示，該交易目前正在進行中，屬於直接所有權類型。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息